Delayed
Australian S.E.
09:06:53 2024-07-07 pm EDT
|
5-day change
|
1st Jan Change
|
18.33
AUD
|
-0.81%
|
|
+1.16%
|
+81.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
392.6
|
1,060
|
2,209
|
2,300
|
3,263
|
6,184
|
-
|
-
|
Enterprise Value (EV)
1 |
350.1
|
984.2
|
2,187
|
2,187
|
3,149
|
6,070
|
5,978
|
5,838
|
P/E ratio
|
-13
x
|
-21.7
x
|
-27.2
x
|
-21.7
x
|
626
x
|
132
x
|
56
x
|
40.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
113
x
|
203
x
|
291
x
|
14.4
x
|
6.49
x
|
8.31
x
|
6.54
x
|
5.54
x
|
EV / Revenue
|
100
x
|
189
x
|
288
x
|
13.7
x
|
6.27
x
|
8.16
x
|
6.32
x
|
5.23
x
|
EV / EBITDA
|
-14.3
x
|
-28.5
x
|
-31.2
x
|
-32.3
x
|
53.9
x
|
59.3
x
|
34.3
x
|
25.7
x
|
EV / FCF
|
-
|
575
x
|
-35.2
x
|
-29.9
x
|
223
x
|
119
x
|
41.5
x
|
29
x
|
FCF Yield
|
-
|
0.17%
|
-2.84%
|
-3.35%
|
0.45%
|
0.84%
|
2.41%
|
3.44%
|
Price to Book
|
5.17
x
|
12.3
x
|
1,024
x
|
28.7
x
|
21.9
x
|
25.1
x
|
16.4
x
|
11.6
x
|
Nbr of stocks (in thousands)
|
253,280
|
280,405
|
285,073
|
316,343
|
323,727
|
334,640
|
-
|
-
|
Reference price
2 |
1.550
|
3.780
|
7.750
|
7.270
|
10.08
|
18.48
|
18.48
|
18.48
|
Announcement Date
|
2/23/20
|
2/25/21
|
2/23/22
|
2/27/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.485
|
5.213
|
7.596
|
160.1
|
502.5
|
744.3
|
946.2
|
1,116
|
EBITDA
1 |
-24.48
|
-34.59
|
-70.07
|
-67.8
|
58.44
|
102.3
|
174.3
|
227.2
|
EBIT
1 |
-28.71
|
-39.47
|
-75.25
|
-73.18
|
51.69
|
90.05
|
165.9
|
219.3
|
Operating Margin
|
-823.93%
|
-757.13%
|
-990.61%
|
-45.71%
|
10.29%
|
12.1%
|
17.53%
|
19.65%
|
Earnings before Tax (EBT)
1 |
-31.12
|
-47.94
|
-80.46
|
-98.62
|
3.087
|
80.23
|
147.8
|
193
|
Net income
1 |
-27.87
|
-44.89
|
-80.51
|
-104.1
|
5.211
|
50.24
|
108.6
|
152.6
|
Net margin
|
-799.63%
|
-861.06%
|
-1,059.9%
|
-65.01%
|
1.04%
|
6.75%
|
11.48%
|
13.67%
|
EPS
2 |
-0.1194
|
-0.1745
|
-0.2850
|
-0.3350
|
0.0161
|
0.1405
|
0.3302
|
0.4602
|
Free Cash Flow
1 |
-
|
1.712
|
-62.05
|
-73.17
|
14.15
|
51
|
144
|
201
|
FCF margin
|
-
|
32.84%
|
-816.93%
|
-45.7%
|
2.82%
|
6.85%
|
15.22%
|
18.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
24.21%
|
49.84%
|
82.63%
|
88.47%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
271.52%
|
101.5%
|
132.58%
|
131.7%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/20
|
2/25/21
|
2/23/22
|
2/27/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q2
|
2023 S1
|
2023 S2
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
---|
Net sales
1 |
1.607
|
-
|
2.91
|
4.686
|
24.05
|
55.3
|
80.75
|
136
|
120.7
|
220.8
|
281.7
|
178
|
356.5
|
178
|
181
|
371
|
EBITDA
|
-
|
-23.56
|
-27.4
|
-
|
-
|
-
|
-
|
-7.046
|
-
|
34.72
|
23.71
|
-
|
52.7
|
-
|
-
|
49.7
|
EBIT
|
-
|
-
|
-29.94
|
-45.3
|
-63.48
|
-
|
-
|
-9.704
|
-
|
31.53
|
20.16
|
-
|
-6.2
|
-
|
-
|
-6.2
|
Operating Margin
|
-
|
-
|
-1,028.97%
|
-966.79%
|
-263.97%
|
-
|
-
|
-7.13%
|
-
|
14.28%
|
7.16%
|
-
|
-1.74%
|
-
|
-
|
-1.67%
|
Earnings before Tax (EBT)
|
-
|
-28.69
|
-32.45
|
-
|
-70.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-26.59
|
-32.51
|
-
|
-70.89
|
-
|
-
|
-33.19
|
-
|
-
|
19.53
|
-
|
42.5
|
-
|
-
|
38.4
|
Net margin
|
-
|
-
|
-1,117.32%
|
-
|
-294.8%
|
-
|
-
|
-24.39%
|
-
|
-
|
6.93%
|
-
|
11.92%
|
-
|
-
|
10.35%
|
EPS
|
-0.0722
|
-0.1023
|
-0.1156
|
-
|
-0.2307
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/20/20
|
2/25/21
|
8/18/21
|
2/23/22
|
8/17/22
|
10/19/22
|
2/27/23
|
2/27/23
|
8/23/23
|
8/23/23
|
2/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
42.5
|
75.7
|
22
|
113
|
114
|
114
|
206
|
346
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
1.71
|
-62.1
|
-73.2
|
14.1
|
51
|
144
|
201
|
ROE (net income / shareholders' equity)
|
-45.3%
|
-60.2%
|
-198%
|
-253%
|
34.3%
|
23.9%
|
31.7%
|
33.7%
|
ROA (Net income/ Total Assets)
|
-
|
-34.5%
|
-60.2%
|
-57%
|
12%
|
33.6%
|
42.1%
|
37.5%
|
Assets
1 |
-
|
130.2
|
133.8
|
182.6
|
43.32
|
149.4
|
257.8
|
407
|
Book Value Per Share
2 |
0.3000
|
0.3100
|
0.0100
|
0.2500
|
0.4600
|
0.7400
|
1.130
|
1.600
|
Cash Flow per Share
2 |
-0.1000
|
0.0100
|
-0.2100
|
-0.2100
|
0.0700
|
0.1200
|
0.3500
|
0.4200
|
Capex
1 |
0.4
|
0.25
|
2.73
|
9.2
|
9.74
|
13.5
|
14.9
|
17.5
|
Capex / Sales
|
11.56%
|
4.76%
|
35.89%
|
5.75%
|
1.94%
|
1.82%
|
1.57%
|
1.56%
|
Announcement Date
|
2/23/20
|
2/25/21
|
2/23/22
|
2/27/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
18.48
AUD Average target price
18.89
AUD Spread / Average Target +2.21% Consensus |
1st Jan change
|
Capi.
|
---|
| +83.33% | 4.17B | | +18.97% | 45.34B | | +41.98% | 40.42B | | -10.06% | 37.92B | | +31.15% | 31.75B | | -7.79% | 27.71B | | +13.32% | 26.52B | | +43.05% | 13.96B | | +31.28% | 12.44B | | -7.41% | 11.26B |
Other Biotechnology & Medical Research
|